Martin Shkreli, the investor and drug-company executive once dubbed "Pharma Bro", violated the lifetime ban that bars him from the pharmaceutical industry — and did so while livestreaming, the US Federal Trade Commission alleges, according to Ars Technica.
The ban dates back to a 2022 settlement with the FTC and the New York attorney general. It followed the episode that made Shkreli a household name: his company's decision to raise the price of Daraprim, an antiparasitic drug used in toxoplasmosis, by more than 5,000% overnight. The agreement barred him from the pharmaceutical business for life — one of the stiffest personal sanctions ever imposed in a US drug-pricing case.
What makes the new allegation striking is the medium. The commission's position, as reported, is that Shkreli's public livestreams themselves provide evidence of conduct the ban forbids — a reminder that a lifetime prohibition is only as strong as the enforcement behind it, and that the enforcer now has an unusually public paper trail to work with.
Shkreli's own product stream and history of public comment have repeatedly drawn legal and regulatory scrutiny; a livestream is simultaneously a promotional channel and a discoverable record. Early reports did not fully detail the specific conduct alleged, the remedies the FTC is seeking, or how Shkreli has responded.
Why it matters: the case tests how far a lifetime industry ban reaches in the era of always-on streaming. If a single public broadcast can be the basis for an enforcement action, the practical cost of flouting a ban goes up — as does the credibility of the FTC's drug-pricing settlements as a deterrent.
